<DOC>
	<DOC>NCT00931268</DOC>
	<brief_summary>The study is being undertaken to establish the effectiveness and safety of Macrolane volume restoration factor 30 (VRF30) when used for treatment of HIV-infected subjects with buttocks lipoatrophy.</brief_summary>
	<brief_title>Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>Have buttocks lipoatrophy and is unable to remain seated for more than 30 minutes due to pain. Have undergone HIV treatment for more than 2 years. Have RNA copies less than 50/ml. Have CD4 more than 200 cell/mm3. Active infections. Active skin disease, inflammation or related conditions. Perineal pathology. Condition that may affect pain assessment. Skin with underlying fibrous tissue. BMI less than 19. Insufficient tissue cover in the area to be treated. Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation within 14 days prior to treatment, or a history of bleeding disorders. Permanent implant placed in the treatment area. Other injectable implant, liposuction or other surgical therapy in the treatment area. Presence or history of connective tissue diseases. Tumors or premalign tissue disorder near or on the area to be treated. Contraindications for MRI Previous hypersensitivity to hyaluronic acid, or to the local anesthetic or antibiotic used in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Lipoatrophy</keyword>
	<keyword>Buttock treatment</keyword>
</DOC>